OM Pharma SA

3 trials Commercial sponsor Merged from 2 name variants

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

0 Recruiting

3 Completed trials

4 Countries active

1 Unique IMPs

100% Results reported

Phase II

Phase IV

Phase I

Phase II: 1 Phase IV: 1 Phase I: 1

100%

3 of 3 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top IMPs

LYOPHILIZED BACTERIAL LYSATES OF: HAEMOPHILUS INFLUENZAE STREPTOCOCCUS (DIPLOCOCCUS) PNEUMONIAE KLEBSIELLA PNEUMONIAE AND OZAENAE STAPHYLOCOCCUS AUREUS STREPTOCOCCUS PYOGENES AND VIRIDANS MORAXELLA (BRANHAMELLA / NEISSERIA) CATARRHALIS 2

All trials

3 total

A clinical study investigating OM-85 efficacy and safety in children suffering from Recurrent Wheezing Ended

2024-511083-90-00 Phase II 2 countries LYOPHILIZED BACTERIAL LYSATES OF: HAEMOPHILUS INFLUENZAE STREPTOCOCCUS (DIPLOCOC…
OM 85 in Paediatric Recurrent Respiratory Tract Infections with Wheezing Lower Respiratory Illness Ended

2024-511581-37-00 Phase IV 4 countries LYOPHILIZED BACTERIAL LYSATES OF: HAEMOPHILUS INFLUENZAE STREPTOCOCCUS (DIPLOCOC…
A clinical study investigating OM-85-IN safety and tolerability in healthy volunteers and mild allergic asthma patients Ended

2022-503053-19-00 Phase I 1 country

Showing 1–3 of 3 trials

← All sponsors A–Z